CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Relapsed or Refractory Chronic Lymphocytic Leukemia
DRUG: CYC065|DRUG: Venetoclax
Number of patients who experience dose-limiting toxicity (DLT), At the end of cycle 1 (each cycle is 28 days)
Pharmacokinetic effect, Plasma drug level, At the end of cycle 1 (each cycle is 28 days)|Pharmacodynamic effect, MCL-1 level in peripheral white blood cells, At the end of cycle 1 (each cycle is 28 days)
Anti-tumor activity, Response assessed by investigators based on International Workshop for CLL criteria or International Working Group criteria for patients with small lymphocytic lymphoma., From the date of first dose of CYC065 to 4 weeks after the last dose of CYC065
This is an open-label, single arm, dose escalation study in patients with relapsed or refractory CLL. Treatment will be administered on an outpatient basis and all patients will receive CYC065 over 4-hour infusion once every 2 weeks on Day 1 and Day 15 in combination with venetoclax. One treatment cycle is 4 weeks.